Latest Insider Transactions at Natures Sunshine Products Inc (NATR)
This section provides a real-time view of insider transactions for Natures Sunshine Products Inc (NATR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NATURES SUNSHINE PRODUCTS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NATURES SUNSHINE PRODUCTS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 11
2024
|
Steven J. Fasching Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,869
+50.0%
|
$48,773
$17.43 P/Share
|
|
Oct 15
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,300
-3.46%
|
$29,900
$13.02 P/Share
|
|
Oct 14
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,300
-1.92%
|
$16,900
$13.12 P/Share
|
|
Oct 11
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,580
-2.28%
|
$20,540
$13.37 P/Share
|
|
Oct 10
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,000
-4.15%
|
$39,000
$13.39 P/Share
|
|
Oct 09
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,816
-2.45%
|
$23,608
$13.36 P/Share
|
|
Oct 08
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,800
-2.37%
|
$23,400
$13.13 P/Share
|
|
Oct 01
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,399
-1.81%
|
$18,187
$13.54 P/Share
|
|
Sep 26
2024
|
Kevin Gregory Fuller Global Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,070
+50.0%
|
-
|
|
Sep 06
2024
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
2,968
+3.69%
|
-
|
|
Sep 06
2024
|
Jonathan David Lanoy SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,653
-5.31%
|
$34,489
$13.05 P/Share
|
|
Jul 21
2024
|
Tracee Comstock VP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,236
-2.1%
|
$18,540
$15.55 P/Share
|
|
Jul 21
2024
|
Nathan G Brower EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,376
-2.74%
|
$20,640
$15.55 P/Share
|
|
Jul 21
2024
|
Daniel C Norman EVP & President, Asia |
SELL
Payment of exercise price or tax liability
|
Direct |
1,553
-2.41%
|
$23,295
$15.55 P/Share
|
|
Jul 21
2024
|
Bryant J Yates EVP & President, Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
1,553
-1.57%
|
$23,295
$15.55 P/Share
|
|
Jul 21
2024
|
Jonathan David Lanoy SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
341
-0.68%
|
$5,115
$15.55 P/Share
|
|
Jul 21
2024
|
Terrence Moorehead Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,313
-1.8%
|
$139,695
$15.55 P/Share
|
|
Jul 21
2024
|
Martin A. Gonzalez EVP, Global Supply Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
3,787
-6.25%
|
$56,805
$15.55 P/Share
|
|
Jun 26
2024
|
Kevin R. Herbert EVP & President, North America |
SELL
Payment of exercise price or tax liability
|
Direct |
2,406
-7.03%
|
$36,090
$15.0 P/Share
|
|
Jun 06
2024
|
Bryant J Yates EVP & President, Europe |
SELL
Open market or private sale
|
Direct |
3,068
-3.01%
|
$46,020
$15.3 P/Share
|
|
May 06
2024
|
John Christopher Teets Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,236
+8.65%
|
-
|
|
May 06
2024
|
Robert D Straus Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,236
+10.63%
|
$99,484
$19.1 P/Share
|
|
May 06
2024
|
Richard D Moss Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,236
+11.94%
|
$99,484
$19.1 P/Share
|
|
May 06
2024
|
Tess Roering Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,236
+19.28%
|
$99,484
$19.1 P/Share
|
|
May 06
2024
|
Curtis Kopf Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,236
+19.28%
|
$99,484
$19.1 P/Share
|
|
May 06
2024
|
Heidi Wissmiller Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,236
+15.22%
|
$99,484
$19.1 P/Share
|
|
May 06
2024
|
Rong Yang Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,236
+19.05%
|
$99,484
$19.1 P/Share
|
|
Apr 20
2024
|
Bryant J Yates EVP & President, Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
1,864
-1.8%
|
$35,416
$19.29 P/Share
|
|
Apr 20
2024
|
Jonathan David Lanoy SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,074
-2.09%
|
$20,406
$19.29 P/Share
|
|
Apr 20
2024
|
Daniel C Norman EVP & President, Asia |
SELL
Payment of exercise price or tax liability
|
Direct |
1,864
-2.82%
|
$35,416
$19.29 P/Share
|
|
Apr 20
2024
|
Nathan G Brower EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,534
-2.97%
|
$29,146
$19.29 P/Share
|
|
Apr 20
2024
|
Tracee Comstock VP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,270
-2.11%
|
$24,130
$19.29 P/Share
|
|
Apr 20
2024
|
Leslie Shane Jones EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,747
-2.7%
|
$52,193
$19.29 P/Share
|
|
Apr 20
2024
|
Martin A. Gonzalez EVP, Global Supply Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
1,997
-3.19%
|
$37,943
$19.29 P/Share
|
|
Apr 20
2024
|
Terrence Moorehead Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,560
-1.81%
|
$181,640
$19.29 P/Share
|
|
Apr 11
2024
|
Daniel C Norman EVP & President, Asia |
BUY
Grant, award, or other acquisition
|
Direct |
1,015
+1.51%
|
-
|
|
Mar 29
2024
|
Terrence Moorehead Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,157
-0.78%
|
$83,140
$20.77 P/Share
|
|
Mar 26
2024
|
Jonathan David Lanoy SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
195
-0.38%
|
$3,900
$20.09 P/Share
|
|
Mar 26
2024
|
Tracee Comstock VP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
635
-1.04%
|
$12,700
$20.09 P/Share
|
|
Mar 26
2024
|
Nathan G Brower EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
748
-1.43%
|
$14,960
$20.09 P/Share
|
|
Mar 26
2024
|
Daniel C Norman EVP & President, Asia |
SELL
Payment of exercise price or tax liability
|
Direct |
898
-1.36%
|
$17,960
$20.09 P/Share
|
|
Mar 26
2024
|
Bryant J Yates EVP & President, Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
898
-0.86%
|
$17,960
$20.09 P/Share
|
|
Mar 11
2024
|
Daniel C Norman EVP & President, Asia |
BUY
Grant, award, or other acquisition
|
Direct |
11,311
+14.62%
|
-
|
|
Mar 11
2024
|
Bryant J Yates EVP & President, Europe |
BUY
Grant, award, or other acquisition
|
Direct |
10,532
+9.14%
|
-
|
|
Mar 11
2024
|
Sarah Crockett Global Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,906
+32.44%
|
-
|
|
Mar 11
2024
|
Tracee Comstock VP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
7,308
+10.73%
|
-
|
|
Mar 11
2024
|
Terrence Moorehead Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,228
+7.35%
|
-
|
|
Mar 11
2024
|
Jonathan David Lanoy SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,303
+12.4%
|
-
|
|
Mar 11
2024
|
Nathan G Brower EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,687
+14.21%
|
-
|
|
Mar 11
2024
|
Martin A. Gonzalez EVP, Global Supply Chain |
BUY
Grant, award, or other acquisition
|
Direct |
11,311
+15.3%
|
-
|